Mitochondrial dysfunction and senescence accompany glioblastoma cell death triggered by a putative metabolic...

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Glioblastoma (GBM) is an aggressive brain cancer with poor outcomes, necessitating new treatments.
• Metabolic reprogramming is a key characteristic of cancer, offering therapeutic targets.
• Stiripentol (STP), an anti-epileptic drug, was previously investigated for GBM treatment due to its potential lactate dehydrogenase (LDH) inhibition.

Purpose of the Study:

• To clarify the precise mechanism of action of stiripentol (STP) in glioblastoma (GBM).
• To evaluate STP's potential as a therapeutic agent for GBM by understanding its cellular and metabolic effects.

Main Methods:

• A multiomic approach was utilized to analyze cellular and metabolic changes.
• In vitro metabolic and cellular assays were performed on GBM cells treated with STP.
• Lactate dehydrogenase (LDH) inhibition potency and downstream cellular effects were assessed.

Main Results:

• STP treatment induced significant genetic and metabolic alterations in GBM cells.
• STP exhibited moderate, but not potent, inhibition of LDH.
• Observed cellular changes included increased reactive oxygen species, decreased mitochondrial membrane potential, and induced senescence.

Conclusions:

• STP's anti-cancer effects in GBM appear to be linked to inducing senescence and oxidative stress, beyond direct LDH inhibition.
• Further investigation of senescence-inducing agents and novel LDH inhibitors holds promise for developing new GBM therapeutics.